Geron (id:7711 GERN)
4.07 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 8:33:56 AM)
Exchange closed, opens in 1 day
2.26 USD (2.26%)
11.81 USD (11.81%)
-3.78 USD (-3.78%)
17.29 USD (17.29%)
106.60 USD (106.60%)
213.08 USD (213.08%)
8.24 USD (8.24%)
-36.68 USD (-36.68%)
About Geron
Market Capitalization 2.29B
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
| Headquarters (address) |
919 East Hillsdale Boulevard Foster City 94404 CA United States |
| Phone | 650 473 7700 |
| Website | https://www.geron.com |
| Employees | 141 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | GERN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.64 - 5.34 |
| Market Capitalization | 2.29B |
| P/E trailing | -12.72 |
| P/E forward | -47.25 |
| Price/Sale | 77.51 |
| Price/Book | 7.79 |
| Beta | 0.515 |
| EPS | -0.320 |
| EPS United States (ID:6, base:3402) | 24.22 |